Mark Mann

Toronto Innovation Acceleration Partners joins with biotech giant Amgen to fund disruptive technologies

Mark Mann
September 11, 2019

The commercialization organization formerly known as MaRS Innovation announced a new collaboration with the biotechnology company Amgen, to identify and jointly fund disruptive technologies derived from discovery research conducted in Toronto.

... Please become a Member or login to read the rest of this article ...


Other stories mentioning these organizations, people and topics
Organizations: AMGen, Amgen Canada, Evotec, LAB150, Toronto Innovation Partners (TIAP), and University Hospital Network
People: Francesco Di Marco, Philip Tagari, and Rafi Hofstein
Topics: Commercialization, disruptive technologies, drug discovery, and pharmaceutical sector

Other News

The Short Report, Sept 11, 2019: Genome lab, industrial IoT, ecommerce

Report: Edmonton's downtown tech ecosystem offers fertile ground for growth

The Short Report, September 4, 2019: Master of Information, ocean protection, beef research

Investment firm offers novel income-sharing approach to funding students' education






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 0 free articles remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.